Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015

Brazilian Journal of Infectious Diseases

Volumn 21, Issue 3, 2017, Pages 343-348

  Karlowsky, James A ^a   Hoban, Daryl J ^a,b   Hackel, Meredith A ^b   Lob, Sibylle H ^b   Sahm, Daniel F ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b International Health Management Associates Inc   (United States)

Author keywords

Ertapenem; Imipenem; SMART; Surveillance

Indexed keywords

AMIKACIN; BETA LACTAM; CEFEPIME; CEFTAZIDIME; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTER; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SOUTH AND CENTRAL AMERICA; URINARY TRACT INFECTION; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 85018309136     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2017.03.006     Document Type: Article

References (17)

1. Rice, L.B., Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197 (2008), 1079–1081.
2. Boucher, H.W., Talbot, G.H., Bradley, J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Society of America. Clin Infect Dis 48 (2009), 1–12.
3. Rice, L.B., Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 31:Suppl. 1 (2010), S7–S10.
4. Morrissey, I., Hackel, M., Badal, R., Bouchillon, S., Hawser, S., Biedenbach, D., A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 6 (2013), 1335–1346.
5. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing. Twenty-Fifth Informational Supplement M100-S25. CLSI, Wayne, PA, USA, 2015.
6. Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Tenth Edition: Approved Standard M07-A10. 2015, CLSI, Wayne, PA, USA.
7. Jones, R.N., Guzman-Blanco, M., Gales, A.C., et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz J Infect Dis 17 (2013), 672–681.
8. Villegas, M.V., Blanco, M.G., Sifuentes-Osorino, J., Rossi, F., Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America – 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis 15 (2011), 34–39.
9. Paterson, D., Rossi, F., Baquero, F., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 55 (2005), 965–973.
10. Lob, S.H., Hoban, D.J., Sahm, D.F., Badal, R.E., Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 47 (2016), 317–332.
11. Llaca-Díaz, J.M., Mendoza-Olazarán, S., Camacho-Ortiz, A., Flores, S., Garza-González, E., One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy 58 (2012), 475–481.
12. Brusselaers, N., Vogelaers, D., Blot, S., The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care, 1, 2011, 47.
13. Sader, H.S., Farrell, D.J., Flamm, R.K., Jones, R.N., Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78 (2014), 443–448.
14. Lob, S.H., Biedenbach, D.J., Badal, R.E., et al. Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013. J Glob Antimicrob Resist 3 (2015), 190–197.
15. Karlowsky, J.A., Hoban, D.J., Hackel, M.A., et al. Antimicrobial susceptibility of gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013–2015. J Med Microbiol 66 (2017), 61–69.
16. Solomkin, J.S., Mazuski, J.E., Bradley, J.S., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 133–164.
17. Rossi, F., The challenges of antimicrobial resistance in Brazil. Clin Infect Dis 52 (2011), 1138–1143.